Literature DB >> 4586144

Chemotherapeutic activity of 5-fluorocytosine and amphotericin B against Candida albicans in mice.

E Titsworth, E Grunberg.   

Abstract

The effect of treatment with combinations of the two antifungal agents, 5-fluorocytosine (5-FC) and amphotericin B (AB), against systemic Candida albicans infections in mice was investigated. Graded doses of the single substances and of combinations of the drugs were administered daily for 21 days. The 50% curative dose (CD(50)) values were calculated on the basis of the presence or absence of C. albicans in cultures prepared from the kidneys of animals that succumbed during the experimental period or were sacrificed at the termination of the experiments. Overall, when graded doses of AB were administered in the presence of a constant, inactive dose of 5-FC (approximately one-half to one-fourth the CD(50) of 5-FC), the CD(50) values for AB were lower than those for amphotericin B alone. Similarly, the CD(50)s for 5-FC were reduced when AB was administered at a constant dose equal to one-half to one-fourth the CD(50) of AB alone. In no instance was there evidence of antagonism.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4586144      PMCID: PMC444547          DOI: 10.1128/AAC.4.3.306

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  Amphotericin B toxicity. A follow-up report of 53 patients.

Authors:  R P Miller; J H Bates
Journal:  Ann Intern Med       Date:  1969-12       Impact factor: 25.391

2.  Treatment of Candida sepsis and Cryptococcus meningitis with 5-fluorocytosine. A new antifungal agent.

Authors:  D Tassel; M A Madoff
Journal:  JAMA       Date:  1968-10-21       Impact factor: 56.272

3.  5-fluorocytosine: a replacement for amphotericin B in the treatment of candida and cryptococcus neoformans infections?

Authors:  G A Pankey; W R Lockwood; J M Montalvo
Journal:  J La State Med Soc       Date:  1970-12

4.  5-Fluorocytosine in human cryptococcosis.

Authors:  J P Utz; B S Tynes; H J Shadomy; R J Duma; M M Kannan; K N Mason
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1968

5.  Candida endocarditis treated with 5-fluorocytosine.

Authors:  C O Record; J M Skinner; P Sleight; D C Speller
Journal:  Br Med J       Date:  1971-01-30

6.  5-fluorocytosine in the treatment of cryptococcal and candida mycoses.

Authors:  R J Fass; R L Perkins
Journal:  Ann Intern Med       Date:  1971-04       Impact factor: 25.391

7.  Combined antibiotic action: some definitions and correlations between laboratory and clinical results.

Authors:  E Jawetz
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1967

8.  Clinical use of combinations of antimicrobial agents.

Authors:  W R McCabe
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1967

9.  Mechanism of resistance to antibiotic synergism in enterococci.

Authors:  R A Zimmermann; R C Moellering; A N Weinberg
Journal:  J Bacteriol       Date:  1971-03       Impact factor: 3.490

10.  Two cases of cryptococcal meningitis, one treated with 5-fluorocytosine.

Authors:  J S Watkins; M J Campbell; D Gardner-Medwin; H R Ingham; I G Murray
Journal:  Br Med J       Date:  1969-07-05
View more
  18 in total

Review 1.  Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance.

Authors:  M A Ghannoum; L B Rice
Journal:  Clin Microbiol Rev       Date:  1999-10       Impact factor: 26.132

2.  In vitro studies with combinations of 5-fluorocytosine and amphotericin B.

Authors:  S Shadomy; G Wagner; E Espinel-Ingroff; B A Davis
Journal:  Antimicrob Agents Chemother       Date:  1975-08       Impact factor: 5.191

Review 3.  Combination antifungal therapy.

Authors:  Melissa D Johnson; Conan MacDougall; Luis Ostrosky-Zeichner; John R Perfect; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

4.  History of medical mycology in the united states.

Authors:  A Espinel-Ingroff
Journal:  Clin Microbiol Rev       Date:  1996-04       Impact factor: 26.132

Review 5.  In vitro and in vivo evaluation of antifungal agents.

Authors:  A Espinel-Ingroff; S Shadomy
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-04       Impact factor: 3.267

6.  The place of elective vitrectomy in the management of patients with Candida endophthalmitis.

Authors:  T Barrie
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1987       Impact factor: 3.117

7.  Chemotherapy of experimental endogenous Candida albicans endophthalmitis.

Authors:  D B Jones
Journal:  Trans Am Ophthalmol Soc       Date:  1980

8.  Therapy of murine aspergillosis with amphotericin B in combination with rifampin of 5-fluorocytosine.

Authors:  J Arroyo; G Medoff; G S Kobayashi
Journal:  Antimicrob Agents Chemother       Date:  1977-01       Impact factor: 5.191

Review 9.  Challenges in the Polyene- and Azole-Based Pharmacotherapy of Ocular Fungal Infections.

Authors:  Prit Lakhani; Akash Patil; Soumyajit Majumdar
Journal:  J Ocul Pharmacol Ther       Date:  2018-11-08       Impact factor: 2.671

10.  Activity of amphotericin B, 5-fluorocytosine, and rifampin against six clinical isolates of Aspergillus.

Authors:  M Kitahara; V K Seth; G Medoff; G S Kobayashi
Journal:  Antimicrob Agents Chemother       Date:  1976-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.